 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 25, 2023 Graf Acquisition Corp. IV Announces Adjournment of...

Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 25, 2023

Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 20, 2023 Graf Acquisition Corp. IV Announces Adjournment of...

Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 20, 2023

Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 13, 2023 Graf Acquisition Corp. IV Announces Adjournment of...

Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 13, 2023

THE WOODLANDS, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR-UN, GFOR-WT) (the Company or Graf), announced today that it intends to adjourn, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the ...

Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023

Special Meeting of Graf Stockholders to Approve Proposed Business Combination to be Held on August 30, 2023 Post-Combination Company s Securities to be Listed on Nasdaq Under Ticker Symbols NKGN...

Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Effectiveness of Form S-4 for Proposed Business Combination

SANTA ANA, Calif. and THE WOODLANDS, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (NKGen or the Company), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (NK) cell therapies, and ...

NKGen Biotech and Graf Acquisition Corp. IV Announce the Nomination of Two Independent Directors for the Board of Directors of the Post-Business Combination Public Company

SANTA ANA, Calif. and THE WOODLANDS, Texas, July 06, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (NKGen), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (NK) cell therapies, and Graf Acquisition ...

NKGen Biotech Inc. and Graf Acquisition Corp. IV to Co-Host Investor Event

Graf Acquisition Corp. IV (NYSE: GFOR) (Graf), announced today that it has been informed that it currently has received stockholder votes from more than 65% of its stockholders to approve the Extension to September 29, 2023. Graf stockholders will cast their votes to approve the Extension at the...

Graf Acquisition Corp. IV Currently Has Proxies from More Than 65% of its Stockholders to Approve Extension

NKGen Biotech, Inc. (NKGen), a clinical stage Natural Killer (NK) cell therapy company, has entered into a merger agreement with Graf Acquisition Corp. IV NKGen Biotech, Inc.s non-genetically modified, enhanced and expanded NK cells have the potential to be a possible treatment for Alzheimers and ...

NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV

Graf Acquisition Corp. IV (NYSE: GFOR) (Graf), a NYSE-listed special purpose acquisition company founded by serial SPAC founder James Graf, and NKGen Biotech, Inc. (NKGen Biotech), a biotechnology company focused on harnessing the power of the bodys immune system through the development of natural...

Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination

Graf Acquisition Corp. IV is a blank check company, which was formed for the purpose of effecting into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The firm's target business candidates include investment bankers and investment professionals. The company was founded on January 28, 2021 and is headquartered in The Woodlands, TX.

Watchers	78
52-Wk Low	$6.56
52-Wk High	$12.88

Market Cap	$68.05M
Volume (M)	2,559.00
52-Wk High	$12.88
52-Wk Low	$6.56

GFOR Graf Acquisition Corp IV

About

Feed

News

Fundamentals